MUMBAI and BALTIMORE — Lupin on Wednesday announced the launch of its generic of Vigamox (moxifloxacin hydrochloride, 0.5%) ophthalmic solution. The drug is indicated to treat bacterial conjunctivitis caused by susceptible strains of the organisms.
Vigamox had U.S. sales of approximately $267.9 million, according to Quintiles IMS data for the 12 months ended March 2017.